MiR-504-3p Has Tumor-Suppressing Activity and Decreases IFITM1 Expression in Non-Small Cell Lung Cancer Cells
Publication: Genetic Testing and Molecular Biomarkers
Volume 26, Issue Number 7-8
Abstract
Objective: To analyze the impact of expression of miR-504-3p on the proliferation, migration, cell cycle transit and rate of apoptosis of NSCLC cells and explore the underlying mechanisms.
Methods: The Cancer Genome Atlas (TCGA) database was used to compare the expression levels of miR-504 between NSCLC tissues and normal lung tissues. NSCLC cells were transfected with lentiviral vectors that either overexpressed or knocked down miR-504-3p to evaluate its effects on NSCLC biological behavior. Quantitative Real Time Polymerase Chain Reaction was used to measure the levels of miR-504-3p and Interferon-Induced Transmembrane Protein 1 (IFITM1). A luciferase reporter array was used to reveal whether miR-504-3p directly targets IFITM1.
Results: The expression of miR-504 was significantly down-regulated in lung cancer tissues compared to normal lung tissues. Overexpression of miR-504-3p in NSCLC cell lines inhibited cell proliferation, migration and promoted cell apoptosis. Meanwhile, changes in the expression level of miR-504-3p had no significant effect on NSCLC cell cycle progression. Moreover, over-expressed miR-504-3p following its transfection significantly decreased the expression of IFITM1 in NSCLC cell lines and suppressed the activity of the luciferase reporter containing wild type but not mutant IFITM1 3′ -UTR.
Conclusion: miR-504-3p inhibits cell proliferation and migration and promotes cell apoptosis in NSCLC cells. MiR-504-3p decreases IFITM1 expression in NSCLC cells, which may be a potential mechanism of its tumor-suppressive functions in NSCLC.
Introduction
Lung cancer is one of the most common human malignant tumors in the world and non-small cell lung cancer (NSCLC) accounts for ∼85% of all cases. Although we have made great progress in the diagnosis and treatment of lung cancer, the prognosis and survival of patients are still unsatisfactory (Bade and Dela Cruz, 2020). Therefore, novel diagnostic and therapeutic strategies for NSCLC are in rapid development.
MicroRNAs (miRNAs) are a type of small molecule noncoding RNA. Half of them are located in the fragile sites of tumor chromosomes (Tutar et al, 2014). Mature miRNA is complementary or noncomplementary to the 3′-untranslated region (3′-UTR) of the target messenger RNA (mRNA) under the guidance of RNA-induced silencing complex after pairing (Krol et al, 2010). It can interfere with or inhibit the expression of mRNA, thereby negatively regulating the target gene at the post-transcriptional level (Correia de Sousa et al, 2019). Emerging evidence has confirmed that miRNAs exert important biological functions in tumorigenesis and development (Mishra et al, 2016; Vishnoi and Rani, 2017), especially in lung cancer (Wu et al, 2018).
Furthermore, the underlying mechanisms were also widely reported. Previous research has found that miR-504 has a biological effect of suppressing cancer in a variety of malignant tumors. For instance, miRNA-504 can suppress hepatocellular carcinoma by inhibiting Frizzled-7-mediated-Wnt/β-catenin signaling (Quan et al, 2018). In addition, miRNA-504 inhibited tumor cell proliferation and invasion by acting on AGE-1 in retinoblastoma (Wang et al, 2019). Meanwhile, research on the role of miRNA-504 in NSCLC has gradually emerged. A recent study incorporating 55 NSCLC cases revealed that the expression of miR-504 was lower in NSCLC tissues and associated with TNM stage and lymph node metastasis in NSCLC patients. Moreover, miR-504 inhibited cell proliferation, invasion, and epithelial-mesenchymal transition (EMT) through targeting LOXL2 in NSCLC (Ye et al, 2018). However, more significant reports on miR-504-3p about its effect or functional mechanism in NSCLC were hardly found.
The interferon-induced transmembrane (IFITM) family were first discovered as interferon-induced genes in human neuroblastoma cells (Friedman et al, 1984). Despite the functions in osteoblast (Hanagata et al, 2011), germ cell specification (Lange et al, 2003; Saitou et al, 2002), adaptive immunity (Bedford et al, 2019; Wakim et al, 2013), and antiviral activity (Bailey et al, 2014; Shi et al, 2020), their crucial roles in tumors have been called for great concern (Liang et al, 2020). Interferon-induced transmembrane protein 1 (IFITM1), which is also known as 9–27 or Leu13, is reported to be highly correlated to prognosis and therapeutic resistance in certain tumor types, such as colorectal cancer (Yu et al, 2015), gallbladder cancer (Li et al, 2019a), and gastric and esophageal adenocarcinoma (Borg et al, 2016). Nevertheless, the role that IFITM1 plays in lung cancer was rarely reported (Sakamoto et al, 2020; Tutar et al, 2014; Yang et al, 2019).
In this study, we investigated the role of miR-504-3p in growth, migration, and cell apoptosis of NSCLC cells. Moreover, we demonstrated that miR-504-3p negatively regulated IFITM1, which may be one of the underlying mechanisms of its tumor-suppressive functions.
Materials and Methods
Cell culture and transfected
H226 and A549 cells (Sangon, Shanghai, China) were used in this study. All cells were cultured with Dulbecco's modified Eagle's medium supplemented with 10% fetal bovine serum (FBS) in a 5% CO2 incubator at 37°C. The miR-504-3p overexpression sequence (5′-CGAAACACCGGGAGTGGA-3′) and knockdown sequence (5′-GGGAGTGCAGGGCAGGGT-3′) were amplification by polymerase chain reaction (PCR) and cloned into PCMV-GV309 vector. The vectors were co-transfected with pHelper1.0 and pHelper2.0 (Biovetor, Beijing, China) into lentivirus packaging cells 239T (Sangon). The concentrated and purified lentivirus were transfected to H226 and A549 cells using HitransG (Genechem, Shanghai, China).
Quantitative real-time polymerase chain reaction
Total RNA from transfected cells was extracted using Trizol (Pufei, Shanghai, China) for both miRNA and IFITM1-mRNA analyses. For analysis of miR-504-3p expression, quantitative real-time (qRT)-PCR was performed using Bulge-Loop™ miRNA qPCR Primer Set (Ribobio, Guangzhou, China) according to the manufacturer's instructions. Relative expression was calculated by comparative cycle threshold (Ct) method and normalized to the expression of U6 small RNA. IFITM1-mRNA was quantified by qRT-PCR using Quantitect SYBR Master PCR Kit (Takara Bio, Shiga, Japan) and normalized to glyceraldehyde-3-phosphate dehydrogenase (GAPDH). PCR primers were as follows: IFITM1, 5′-TCCGTGAAGTCTAGGGACAG-3′ (forward) and 5′-GTCACAGAGCCGAATACCAG-3′ (reverse) and GAPDH, 5′-TGACTTCAACAGCGACACCCA-3′ (forward) and 5′-CACCCTGTTGCTGTAGCCAAA-3′(reverse). All qRT-PCRs were performed in triplicate.
Western blot
Radio immuno precipitation assay buffer (Beyotime Biotechnology, Shanghai, China) blending with phenylmethylsulfonyl fluoride (PMSF) protease inhibitors (Thermo Fisher, Waltham, MA) was used to lyse cells. The protein was extracted using Protein Extraction Reagent A and B (Yeasen, Shanghai, China). Separated protein on 10% sodium dodecyl sulfate-polyacrylamide gelelectrophoresis by equal amounts and transferred it to polyvinylidene difluoride membranes (Pall, NY). Incubated membranes with primary antibodies in 5% nonfat powdered milk configured with Tris-Buffered Saline and Tween 20 and secondary antibody in succession. Enhanced chemiluminescence was used to determine the bands. Primary antibodies anti-IFITM1 and anti-GAPDH were purchased from Abcam (Cambridge, United Kingdom).
Cell proliferation assays
For the cell proliferation assay, cells were plated in 96-well plates (Corning, Glendale, AZ) at 2000 cells/well and incubated for 24 h after transfection of lentiviral vector with different expression levels of miR-504-3p. At the end of incubation, thiazolyl blue tetrazolium bromide (MTT) were added into each well and incubated for 4 h at 37°C. After that, dimethyl sulfoxide was added to dissolve Formazan crystals formed by MTT reduction. Cell viability was tested every 24 h for 120 h in total through evaluating the viable cell numbers by measurement of optical density at 490 nm using the microplate reader (Tecan, Seestrasse, Switzerland).
Cell migration assays
Cell migration was assessed using 3422 Transwell Kit (Corning) according to the manufacturer's introduction. In brief, cells were trypsinized (Thermo Fisher), washed, resuspended in serum-free RPMI1640 (Corning) and placed in the top portion of the chamber. Added 30% FBS to the lower portion of the chamber. The chambers were incubated at 37°C in 5% CO2 for 24 h, washed with phosphate buffered saline, and fixed in 100% methanol. After fixation, cells were stained with GIEMSA (Sigma-Aldrich, Darmstadt, Germany) and imaged by inverted microscope (Caikon, Shanghai, China). The number of migrating cells was counted in nine random fields at 100-fold magnification. Assays were conducted in duplicates.
Cell apoptosis assay
Cell apoptosis was measured using the Annexin-V-APC Apoptosis Detection Kit (Thermo Fisher). Twenty-four hours after the transfection for overexpression or knockdown of miR-504-3p, cells were trypsinized, washed, and resuspended in RPMI1640. Then stained the cells with Annexin V-APC. Finally, analyzed the percentage of apoptotic cells by flow cytometry (Becton, Dickinson and Company, NJ).
Cell cycle assay
For the cell cycle analysis, cells were cultured at 37°C for 24 h after transfection. Digested cells with trypsin and resuspended them in complete medium. Cells were washed by precooled Dulbecco phosphate-buffered saline (Corning) and then stained with propidium iodide (Sigma-Aldrich) for 30 min protected from light. The distribution of cells in distinct cell cycle phases ModFit LT3.2 (Verity Software House, Topsham, ME) was used to determine the distribution of cells in different cell cycle phases.
Luciferase reporter assay
A 199 nt nucleotide sequence of IFITM1 mRNA 3′-UTR containing the binding site for miR-504-3p seed sequence was synthesized and inserted into the Xbal site of the pGV272 vector (Promega, Madison, WI) to construct IFITM1-WT, whereas the mutation of the aforementioned nucleotide sequence (mutated at the site expected to bind to miR-504-3p) was inserted to construct IFITM1-Mut. After transfection with miR-504-3p overexpression or knockdown lentiviral vector for 24 h, X-tremegene HP Transfection Reagent (Roche, Basel, Schweiz) was used to transfect cells with wild-type or Mut reporter plasmid vector. After 36 h, Luciferase activity was measured by a dual-luciferase reporter assay system (Promega). The fluorescence intensity of Firefly luciferase was normalized to that of Renilla luciferase for each sample.
Statistical analysis
Statistical analysis was performed using SPSS software (version 19.0; SPSS, Inc., Chicago, IL) and GraphPad Prism 5.0 (GraphPad Software, Inc., La Jolla, CA). The relative miR-504-3p or IFITM1 expression was evaluated by comparative CT method and normalized to the expression of U6 or GAPDH. The results of cell experiments were expressed as mean ± standard deviation and the differences between groups were analyzed by Student's t-test. Differences were considered to be statistically significant at p < 0.05.
Results
Abnormal expression levels of miR-504-3p and its target gene IFITM1 between normal and lung cancer tissues
The available data from The Cancer Genome Atlas (TCGA) revealed that the levels of miR-504-3p were significantly lower both in lung adenocarcinoma (LUAD) and lung squamous cell carcinoma (LUSC) tissues compared with normal lung tissues with the fold change of LUAD versus normal to be 0.68 (p < 0.001). Similarly, the fold change of LUSC versus normal was 0.79 (p = 0.003) (Fig. 1A). Likewise, we analyzed the expression of IFITM1, which was predicted to be the target gene of miR-504-3p through miRanda and TargetScan. The results demonstrated that the levels of IFITM1 were significantly higher in LUAD tissues (fold change of cancer vs. normal = 1.296, p = 0.035). However, the levels of IFITM1 showed no significant difference between LUSC and normal lung tissues. (Fold change of cancer vs. normal = 0.944, p = 0.635) (Fig. 1B). We failed to find a correlation analysis between expression of miR504-3p and IFITM1 indicating an inverse relationship in the TCGA database.
MiR-504-3p suppresses the proliferation of NSCLC cells in vitro
We chose H226 and A549 lung cancer cell lines for transfection with lentiviral vector containing over- or low expression of miR-504-3p to investigate its biological functions. The qRT-PCR results suggested that the level of miR-504-3p in H226 and A549 cells was significantly increased after transfection with overexpression miR-504-3P (p < 0.05). Relatively, transfection with knockdown of miR504-3p markedly decreased the level of miR-504-3p in H226 and A549 cells (p < 0.05) (Fig. 2A). Overexpression of miR-504-3p significantly inhibited the proliferation of H226 and A549 cells 48 h after transfection whereas knockdown of miR-504-3p significantly promoted the proliferation of H226 and A549 cells 48 h after transfection (p < 0.05) (Fig. 2B).
MiR-504-3p suppresses migration of NSCLC cells
We evaluated the effect of miR-504-3p on migration ability of NSCLC cells. The results suggested that migration ability of H226 and A549 cells was significantly reduced after transfection with overexpression of miR-504-3p (p < 0.05), whereas transfection with knockdown of miR-504-3p significantly promoted the migration ability of H226 and A549 cells (p < 0.05) (Fig. 3A, B).
MiR-504-3p promotes the apoptosis of NSCLC cells and makes no significant impact on cell cycle
We further analyzed the effect of miR-504-3p on NSCLC apoptosis and cell cycle to investigate how miR-504-3p regulating the proliferation of NSCLC cell using the flow cytometry assay. The results revealed that overexpression of miR-504-3p significantly advanced the apoptosis of H226 and A549 cells (p < 0.05). Meanwhile, knockdown of miR-504-3p observably decreased the apoptosis of H226 and A549 cells (p < 0.05) (Fig. 4A, B). Besides, no significant difference of cell cycle was shown no matter how expression level of miR-504-3p changed in NSCLC cells (p > 0.05) (Fig. 4C). These results demonstrated that miR-504-3p regulated cell proliferation principally through increasing the apoptosis of NSCLC cells.
IFITM1 is a direct target of MiR-504-3p in NSCLC cells
We predicted the potential target genes of miR-504-3p using bioinformatics algorithms, Tagetscan and miRanda. The results showed that 3′-UTR of the IFITM1 mRNA contains a highly conserved and perfect complementary region from position 26 to 33 for binding the seed sequence of miR-504-3p (GCACUCC paired CGUGAGG) (Fig. 5A), which strongly supported that IFITM1 was one of the target genes of miR-504-3p. To determine whether IFITM1 was truly the target gene of miR-504-3p, we construct the IFITM1-Wt and IFITM1-Mut luciferase reporter plasmids, which contain the wild-type IFITM1 3′-UTR sequence and the 3′-UTR with the 7 nt binding site sequence with miR-504-3p deletion, severally.
We quantified IFITM1-mRNA after transfection using qRT-PCR and normalized to GAPDH. IFITM1 was markedly reduced after miR-504-3p overexpression, whereas increased after miR-504-3p knockdown in H226 and A549 cells according to the results of qRT-PCR and western blot (p < 0.05) (Fig. 5B, C). The luciferase reporter results suggested that overexpression of miR-504-3p significantly decreased the luciferase activity of H226 cells transfected with IFITM1-Wt compared with the negative control (p < 0.05), whereas the deletion mutation of the binding sites eliminated the effect of miR-504-3p on luciferase activity.
In addition, knockdown of miR-504-3p markedly increased the luciferase activity in A549 cells transfected with IFITM1-Wt (p < 0.05), and the mutation abrogated the effect of the low expression level of miR-504-3p on the luciferase activity (Fig. 5C). These results revealed that miR-504-3p regulates the expression of IFITM1 by directly binding to the IFITM1 3′-UTR sequence in NSCLC cells. In other words, IFITM1 is one of the target genes of miR-504-3p.
Discussion
Lung cancer, especially NSCLC, has always been of great concern for its high morbidity and mortality all over the world (Schabath and Cote, 2019). According to statistics, about 1.6 million people died of lung cancer worldwide in 2012, and this number will reach 3.5 million by 2035. Predictably, with the intensification of aging, environmental pollution, and smoking problems, the incidence of lung cancer will further increase, making the worldwide social medical system face severe challenges (Didkowska et al, 2016). Therefore, the early diagnosis, treatment, and molecular biological mechanisms of lung cancer have always been the popular fields.
Emerging evidence has confirmed that miRNAs exert important biological functions in tumorigenesis and development (Lee and Dutta, 2009; Sandiford et al, 2018), especially in lung cancer (Du et al, 2018; Iqbal et al, 2019). For example, miR-127 is related to the poor prognosis of LUAD (Shi et al, 2017). The expression of miR-105-1 in NSCLC tissue was downregulated compared with normal lung tissue, and it was associated with poor overall survival and disease free survival in NSCLC patients (Lu et al, 2017). miR-221 and miR-222 can suppress tumors in most lung cancer cell lines (Yamashita et al, 2015).
Recent reports demonstrated that miRNA-504-3p acted as a tumor suppressor in various cancers. MiR-504-3p exerted inhibiting effects in the proliferation, migration, and invasion of diverse cancer types by targeting different genes. For instance, miR-504 inhibits cell proliferation and promotes apoptosis by targeting FOXP1 in human glioma (Cui et al, 2016). MiR-504-3p may also serve as a tumor suppressor by targeting MTHFD2 in acute myeloid leukemia (Li et al, 2019b). Moreover, miR-504 has been shown to inhibit cell proliferation through targeting CDK6 in hypopharyngeal squamous cell carcinoma (Kikkawa et al, 2014). However, few reports were found on miR-504-3p in lung cancer.
Therefore, we chose miRNA-504-3p as the research object and conducted functional tests of NSCLC cells in vitro to investigate the effect of miRNA-504-3p on the biological behavior of NSCLC in this study. The function study showed that miRNA-504 inhibited the proliferation and migration of NSCLC cells and promoted cell apoptosis. These results suggested that miR-504-3p acted as an antioncogene in NSCLC and the downregulation of miR-504-3p contributes to the progression and metastasis of NSCLC. Experiments in vivo need to be further performed to determine whether targeting miR-504-3p can become a new therapeutic strategy for NSCLC.
IFITM1 is a member of the IFITM protein family (Yánez et al, 2020). Evidence has shown that IFITM1 is highly expressed in tumor tissues and cancer cell lines (Hatano et al, 2008; He et al, 2015). It has been reported that overexpression of IFITM1 promotes tumor cell proliferation, invasion, metastasis (Lee et al, 2012), and angiogenesis (Baeriswyl and Christofori, 2009), and the high expression level of IFITM1 is often associated with resistance to radiotherapy (Guo et al, 2012), chemotherapy (Bani et al, 2004), and endocrine therapy (Xu et al, 2019).
For example, IFITM1 is closely related to lymph node metastasis, distance metastasis, and higher clinical stages in colorectal cancer (Sari et al, 2016). According to the results of a recent research, silencing of IFITM1 inhibited proliferation, migration, and invasion of lung cancer cells (Yan et al, 2019). However, the mechanism of IFITM1 dysregulation in lung cancer is poorly understood. In this study, we revealed a novel mechanism by which IFITM1 is regulated. The luciferase reporter assay demonstrated that IFITM1 was directly targeted by miR-504-3p in NSCLC cells. Nevertheless, whether the dysregulation of IFITM1 is regulated by other mechanisms in NSCLC is not yet known.
Our study has several limitations. There may be other targets for IFITM1. In addition, further analysis for functions of miR-504-3p in vivo is necessary. Next, we will establish an animal model of NSCLC to evaluate the effect of in vivo.
This study analyzed the expression levels and functions of miR-504-3p in NSCLC. The data showed miR-504-3p is downregulated in NSCLC tissues. Results of functional experiment revealed that miR-504-3p execute a tumor-suppressive effect on NSCLC cells. This effect is probably partially on account of directly targeting 3′-UTR of IFITM1 by miR-504-3p. Thus, our findings may suggest novel therapeutic strategies for NSCLC.
References
Bade BC, Dela Cruz CS. Lung cancer 2020: Epidemiology, etiology, and prevention. Clin Chest Med 2020;41(1):1–24;.
Baeriswyl V, Christofori G. The angiogenic switch in carcinogenesis. Semin Cancer Biol 2009;19(5):329–337;.
Bailey CC, Zhong G, Huang IC, et al. IFITM-family proteins: The cell's first line of antiviral defense. Annu Rev Virol 2014;1:261–283;.
Bani MR, Nicoletti MI, Alkharouf NW, et al. Gene expression correlating with response to paclitaxel in ovarian carcinoma xenografts. Mol Cancer Ther 2004;3(2):111–121.
Bedford JG, O'Keeffe M, Reading PC, et al. Rapid interferon independent expression of IFITM3 following T cell activation protects cells from influenza virus infection. PloS One 2019;14(1):e0210132;.
Borg D, Hedner C, Gaber A, et al. Expression of IFITM1 as a prognostic biomarker in resected gastric and esophageal adenocarcinoma. Biomark Res 2016;4:10;.
Correia de Sousa M, Gjorgjieva M, Dolicka D, et al. Deciphering miRNAs' action through miRNA editing. Int J Mol Sci 2019;20(24):6249;.
Cui R, Guan Y, Sun C, et al. A tumor-suppressive microRNA, miR-504, inhibits cell proliferation and promotes apoptosis by targeting FOXP1 in human glioma. Cancer Lett 2016;374(1):1–11;.
Didkowska J, Wojciechowska U, Mańczuk M, et al. Lung cancer epidemiology: contemporary and future challenges worldwide. Ann Transl Med 2016;4(8):150;.
Du X, Zhang J, Wang J, et al. Role of miRNA in lung cancer-potential biomarkers and therapies. Curr Pharm Des 2018;23:5997–6010;.
Friedman RL, Manly SP, McMahon M, et al. Transcriptional and posttranscriptional regulation of interferon-induced gene expression in human cells. Cell 1984;38(3):745–755;.
Guo Y, Zhu XD, Qu S, et al. Identification of genes involved in radioresistance of nasopharyngeal carcinoma by integrating gene ontology and protein-protein interaction networks. Int J Oncol 2012;40(1):85–92;.
Hanagata N, Li X, Morita H, et al. Characterization of the osteoblast-specific transmembrane protein IFITM5 and analysis of IFITM5-deficient mice. J Bone Miner Metab 2011;29(3):279–290;.
Hatano H, Kudo Y, Ogawa I, et al. IFN-induced transmembrane protein 1 promotes invasion at early stage of head and neck cancer progression. Clin Cancer Res 2008;14(19):6097–6105;.
He J, Li J, Feng W, et al. Prognostic significance of INF-induced transmembrane protein 1 in colorectal cancer. Int J Clin Exp Pathol 2015;8(12):16007–16013.
Iqbal MA, Arora S, Prakasam G, et al. MicroRNA in lung cancer: Role, mechanisms, pathways and therapeutic relevance. Mol Aspects Med 2019;70:3–20;.
Kikkawa N, Kinoshita T, Nohata N, et al. microRNA-504 inhibits cancer cell proliferation via targeting CDK6 in hypopharyngeal squamous cell carcinoma. Int J Oncol 2014;44(6):2085–2092;.
Krol J, Loedige I, Filipowicz W. The widespread regulation of microRNA biogenesis, function and decay. Nat Rev Genet 2010;11(9):597–610;.
Lange UC, Saitou M, Western PS, et al. The fragilis interferon-inducible gene family of transmembrane proteins is associated with germ cell specification in mice. BMC Dev Biol 2003;3:1;.
Lee J, Goh SH, Song N, et al. Overexpression of IFITM1 has clinicopathologic effects on gastric cancer and is regulated by an epigenetic mechanism. Am J Pathol 2012;181(1):43–52;.
Lee YS, Dutta A. MicroRNAs in cancer. Annu Rev Pathol 2009;4:199–227;.
Li D, Yang Z, Liu Z, et al. DDR2 and IFITM1 are prognostic markers in gallbladder squamous cell/adenosquamous carcinomas and adenocarcinomas. Pathol Oncol Res 2019a;25(1):157–167;.
Li SM, Zhao YQ, Hao YL, et al. Upregulation of miR-504-3p is associated with favorable prognosis of acute myeloid leukemia and may serve as a tumor suppressor by targeting MTHFD2. Eur Rev Med Pharmacol Sci 2019b;23:1203–1213;.
Liang R, Li X, Zhu X. Deciphering the roles of IFITM1 in tumors. Mol Diagn Ther 2020;24(4):433–441;.
Lu G, Fu D, Jia C, et al. Reduced miR-105-1 levels are associated with poor survival of patients with non-small cell lung cancer. Oncol Lett 2017;14(6):7842–7848;.
Mishra S, Yadav T, Rani V. Exploring miRNA based approaches in cancer diagnostics and therapeutics. Crit Rev Oncol Hematol 2016;98:12–23;.
Quan H, Li B, Yang J. MicroRNA-504 functions as a tumor suppressor in hepatocellular carcinoma through inhibiting Frizzled-7-mediated-Wnt/β-catenin signaling. Biomed Pharmacother 2018;107:754–762;.
Saitou M, Barton SC, Surani MA. A molecular programme for the specification of germ cell fate in mice. Nature 2002;418(6905):293–300;.
Sakamoto S, Inoue H, Kohda Y, et al. Interferon-induced transmembrane protein 1 (IFITM1) promotes distant metastasis of small cell lung cancer. Int J Mol Sci 2020;21(14):4934;.
Sandiford OA, Moore CA, Du J, et al. Human aging and cancer: Role of miRNA in tumor microenvironment. Adv Exp Med Biol 2018;1056:137–152;.
Sari IN, Yang YG, Phi LT, et al. Interferon-induced transmembrane protein 1 (IFITM1) is required for the progression of colorectal cancer. Oncotarget 2016;7(52):86039–86050;.
Schabath MB, Cote ML. Cancer progress and priorities: Lung cancer. Cancer Epidemiol Biomarkers Prev 2019;28(10):1563–1579;.
Shi G, Kenney AD, Kudryashova E, et al. (2020) Opposing activities of IFITM proteins in SARS-CoV-2 infection. EMBO J 2020;40(3):e106501;.
Shi L, Wang Y, Lu Z, et al. miR-127 promotes EMT and stem-like traits in lung cancer through a feed-forward regulatory loop. Oncogene 2017;36(12):1631–1643;.
Tutar L, Tutar E, Tutar Y. miRNA and cancer; computational and experimental approaches. Curr Pharm Biotechnol 2014;15(5):429;.
Vishnoi A, Rani S. miRNA biogenesis and regulation of diseases: An overview. Methods Mol Biol 2017;1509:1–10;.
Wakim LM, Gupta N, Mintern JD, et al. Enhanced survival of lung tissue-resident memory CD8+ T cells during infection with influenza virus due to selective expression of IFITM3. Nat Immunol 2013;14(3):238–245;.
Wang L, Lyu X, Ma Y, et al. MicroRNA-504 targets AEG-1 and inhibits cell proliferation and invasion in retinoblastoma. Mol Med Rep 2019;19(4):2935–2942;.
Wu M, Wang G, Tian W, et al. MiRNA-based therapeutics for lung cancer. Curr Pharm Des 2018;23(39):5989–5996;.
Xu YY, Yu HR, Sun JY, et al. Upregulation of PITX2 promotes letrozole resistance via transcriptional activation of IFITM1 signaling in breast cancer cells. Cancer Res Treat 2019;51(2):576–592;.
Yamashita R, Sato M, Kakumu T, et al. Growth inhibitory effects of miR-221 and miR-222 in non-small cell lung cancer cells. Cancer Med 2015;4(4):551–564.
Yan J, Jiang Y, Lu J, et al. Inhibiting of proliferation, migration, and invasion in lung cancer induced by silencing interferon-induced transmembrane protein 1 (IFITM1). Biomed Res Int 2019;2019:9085435;.
Yánez DC, Ross S, Crompton T. The IFITM protein family in adaptive immunity. Immunology 2020;159(4):365–372;.
Yang YG, Koh YW, Sari IN, et al. Interferon-induced transmembrane protein 1-mediated EGFR/SOX2 signaling axis is essential for progression of non-small cell lung cancer. Int J Cancer 2019;144(8):2020–2032;.
Ye MF, Zhang JG, Guo TX, et al. MiR-504 inhibits cell proliferation and invasion by targeting LOXL2 in non small cell lung cancer. Biomed Pharmacother 2018;97:1289–1295;.
Yu F, Xie D, Ng SS, et al. IFITM1 promotes the metastasis of human colorectal cancer via CAV-1. Cancer Lett 2015;368(1):135–143;.
Information & Authors
Information
Published In
Genetic Testing and Molecular Biomarkers
Volume 26 • Issue Number 7-8 • July/August 2022
Pages: 351 - 359
PubMed: 36027039
Copyright
Copyright 2022, Mary Ann Liebert, Inc., publishers.
History
Published online: 26 August 2022
Published in print: July/August 2022
Topics
Authors
Author Disclosure Statement
No competing financial interests exist.
Funding Information
This study was supported by Science and Technology Development Plan of Soochow (Livelihood Science and Technology) (SS201832) and Medical and Health Scientific and Technological Innovation Program of Soochow (SKJY2021023).
Metrics & Citations
Metrics
Citations
Export Citation
Export citation
Select the format you want to export the citations of this publication.
View Options
View options
PDF/EPUB
View PDF/EPUBAccess content
To read the fulltext, please use one of the options below to sign in or purchase access.⚠ Society Access
If you are a member of a society that has access to this content please log in via your society website and then return to this publication.